Please use this identifier to cite or link to this item:
https://doi.org/10.1038/s41598-018-27950-9
Title: | Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes | Authors: | Li, F.-F Liu, B.-L Yin, G.-P Yan, R.-N Zhang, D.-F Wu, J.-D Ye, L Su, X.-F Ma, J.-H |
Keywords: | antidiabetic agent insulin metformin adult blood blood glucose monitoring combination drug therapy controlled study drug effect female glucose blood level human male middle aged non insulin dependent diabetes mellitus randomized controlled trial subcutaneous drug administration Adult Blood Glucose Blood Glucose Self-Monitoring Diabetes Mellitus, Type 2 Drug Therapy, Combination Female Humans Hypoglycemic Agents Infusions, Subcutaneous Insulin Male Metformin Middle Aged |
Issue Date: | 2018 | Publisher: | Nature Publishing Group | Citation: | Li, F.-F, Liu, B.-L, Yin, G.-P, Yan, R.-N, Zhang, D.-F, Wu, J.-D, Ye, L, Su, X.-F, Ma, J.-H (2018). Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes. Scientific Reports 8 (1) : 9713. ScholarBank@NUS Repository. https://doi.org/10.1038/s41598-018-27950-9 | Rights: | Attribution 4.0 International | Abstract: | To investigate whether metformin add-on to the continuous subcutaneous insulin infusion (Met + CSII) therapy leads to a significant reduction in insulin doses required by type 2 diabetes (T2D) patients to maintain glycemic control, and an improvement in glycemic variation (GV) compared to CSII only therapy. We analyzed data from our two randomized, controlled open-label trials. Newly diagnoses T2D patients were randomized assigned to receive either CSII therapy or Met + CSII therapy for 4 weeks. Subjects were subjected to a 4-day continuous glucose monitoring (CGM) at the endpoint. Insulin doses and GV profiles were analyzed. The primary endpoint was differences in insulin doses and GV between the two groups. A total of 188 subjects were admitted as inpatients. Subjects in metformin add-on therapy required significantly lower total, basal and bolus insulin doses than those of control group. CGM data showed that patients in Met + CSII group exhibited significant reduction in the 24-hr mean amplitude of glycemic excursions (MAGE), the standard deviation, and the coefficient of variation compared to those of control group. Our data suggest that metformin add-on to CSII therapy leads to a significant reduction in insulin doses required by T2D patients to control glycemic variations. © 2018 The Author(s). | Source Title: | Scientific Reports | URI: | https://scholarbank.nus.edu.sg/handle/10635/178405 | ISSN: | 2045-2322 | DOI: | 10.1038/s41598-018-27950-9 | Rights: | Attribution 4.0 International |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1038_s41598-018-27950-9.pdf | 1.25 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License